跳至主要内容
临床试验/NCT00901004
NCT00901004已完成不适用

Non-interventional, Cross-sectional, Multi-center Study to Establish The Clinical Significance of Minimal Change in Reflux Esophagitis Based on the Gastroesophageal Reflux Disease Questionnaire (GerdQ)

AstraZeneca1 个研究点 分布在 1 个国家目标入组 1,550 人开始时间: 2009年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
1,550
试验地点
1
主要终点
To investigate significant minimal change endoscopic finding of reflux esophagitis diagnosis

研究概览

简要总结

The purpose of this study is to define the endoscopic findings of minimal change that is significant to clinical significant reflux esophagitis. Through this, the investigators want to estimate the applicability of minimal change findings of reflux esophagitis to the clinic.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 20 years old patients who consent to revealing their medical information and be able to respond to questionnaires regarding the symptom.
  • Patients who had shown the reflux esophageal minimal change in the endoscopic finding: the reflux esophagitis

排除标准

  • Patients who had shown the mucosal break or barrett esophagus at gastric mucosal barrier or lower oesophagus in endoscopic findings
  • Patient with a diagnosis of gastroesophageal reflux disease and who have received medication treatment
  • Patient who had received H2-receptor antagonists, prostaglandin, PPI, NSAIDs or aspirin, high dose steroid and anticoagulants for at least 5 consecutive days in the 4-week period immediately preceding the diagnostic endoscopy
  • Patients with a history of operation due to gastrointestinal disease, malignancy, alcoholism, pregnancy (in female), breast feeding (in female) or systemic disease

结局指标

主要结局

To investigate significant minimal change endoscopic finding of reflux esophagitis diagnosis

时间窗: Significant minimal change endoscopic finding for gastroesophageal reflux disease diagnosis

次要结局

  • To establish the probability model of diagnosing gastroesophageal reflux disease based on minimal change endoscopic findings through definition of significant minimal change endoscopic findings of gastroesophageal reflux disease diagnosis.(at baseline -->this is a cross-sectional study)

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验